RxDoctor Payments Data

Brittney Harris

Acute Care · Marysville, WANPI 1437791662

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Orexo US, Inc. at 39.3% of the total. 2025 is the largest year on record at $381, more than ten times the $31 reported in 2022.

$595in general payments, 2019–2025

Across 26 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$234
  • AbbVie$150
  • Braeburn Inc.$68
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$62
  • Otsuka America Pharmaceutical, Inc.$26
  • Axsome Therapeutics, Inc.$22
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$595 in reported general payments places this provider in the 75th percentile of 135 acute care providers in Washington.

See all acute care providers in Washington

Medicare billing

Part B allowed, 2024
$20,530
Medicare patients
29
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl208$22,036
SuboxoneBuprenorphine Hcl/Naloxone Hcl20$5,019
Oxybutynin Chloride13$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$13$5,01920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 135 acute care providers in Washington.

Other acute care in Marysville

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →